Denmark
· Delayed Price · Currency is DKK Genmab Statistics
Total Valuation
Genmab has a market cap or net worth of DKK 118.96 billion. The enterprise value is 104.24 billion.
| Market Cap | 118.96B |
| Enterprise Value | 104.24B |
Important Dates
The next estimated earnings date is Wednesday, November 6, 2024.
| Earnings Date | Nov 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Genmab has 63.49 million shares outstanding. The number of shares has decreased by -0.51% in one year.
| Shares Outstanding | 63.49M |
| Shares Change (YoY) | -0.51% |
| Shares Change (QoQ) | -1.18% |
| Owned by Insiders (%) | 1.07% |
| Owned by Institutions (%) | 53.45% |
| Float | 62.82M |
Valuation Ratios
The trailing PE ratio is 22.19 and the forward PE ratio is 24.69. Genmab's PEG ratio is 1.14.
| PE Ratio | 22.19 |
| Forward PE | 24.69 |
| PS Ratio | 6.41 |
| PB Ratio | 3.84 |
| P/FCF Ratio | 18.26 |
| PEG Ratio | 1.14 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.89, with an EV/FCF ratio of 16.00.
| EV / Earnings | 18.82 |
| EV / Sales | 5.48 |
| EV / EBITDA | 15.89 |
| EV / EBIT | 16.83 |
| EV / FCF | 16.00 |
Financial Position
The company has a current ratio of 5.03, with a Debt / Equity ratio of 3.29.
| Current Ratio | 5.03 |
| Quick Ratio | 5.02 |
| Debt / Equity | 3.29 |
| Debt / EBITDA | 0.16 |
| Debt / FCF | 0.16 |
| Interest Coverage | 176.94 |
Financial Efficiency
Return on equity (ROE) is 18.55% and return on invested capital (ROIC) is 12.58%.
| Return on Equity (ROE) | 18.55% |
| Return on Assets (ROA) | 10.97% |
| Return on Capital (ROIC) | 12.58% |
| Revenue Per Employee | 7.53M |
| Profits Per Employee | 2.19M |
| Employee Count | 2,204 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 13.33 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -30.15% in the last 52 weeks. The beta is 0.84, so Genmab's price volatility has been lower than the market average.
| Beta (5Y) | 0.84 |
| 52-Week Price Change | -30.15% |
| 50-Day Moving Average | 1,833.16 |
| 200-Day Moving Average | 1,980.79 |
| Relative Strength Index (RSI) | 54.89 |
| Average Volume (20 Days) | 122,222 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genmab had revenue of DKK 19.02 billion and earned 5.54 billion in profits. Earnings per share was 84.41.
| Revenue | 19.02B |
| Gross Profit | 18.44B |
| Operating Income | 6.19B |
| Pretax Income | 7.52B |
| Net Income | 5.54B |
| EBITDA | 6.46B |
| EBIT | 6.19B |
| Earnings Per Share (EPS) | 84.41 |
Balance Sheet
The company has 15.73 billion in cash and 1.02 billion in debt, giving a net cash position of 14.71 billion or 231.74 per share.
| Cash & Cash Equivalents | 15.73B |
| Total Debt | 1.02B |
| Net Cash | 14.71B |
| Net Cash Per Share | 231.74 |
| Equity (Book Value) | 30.97B |
| Book Value Per Share | 487.96 |
| Working Capital | 17.57B |
Cash Flow
In the last 12 months, operating cash flow was 6.74 billion and capital expenditures -220.00 million, giving a free cash flow of 6.52 billion.
| Operating Cash Flow | 6.74B |
| Capital Expenditures | -220.00M |
| Free Cash Flow | 6.52B |
| FCF Per Share | 102.61 |
Margins
Gross margin is 96.95%, with operating and profit margins of 32.57% and 29.13%.
| Gross Margin | 96.95% |
| Operating Margin | 32.57% |
| Pretax Margin | 39.55% |
| Profit Margin | 29.13% |
| EBITDA Margin | 33.99% |
| EBIT Margin | 32.57% |
| FCF Margin | 34.26% |
Dividends & Yields
Genmab does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.51% |
| Shareholder Yield | 0.51% |
| Earnings Yield | 4.51% |
| FCF Yield | 5.48% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |